Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System

Authors:

Abstract
Immunocompromised individuals (ie, persons with immunocompromising conditions or who are taking immunosuppressive medications) are at increased risk for severe COVID-19.1 Additionally, immunocompromised individuals often mount weaker immune responses to vaccines and experience higher rates of vaccine failure compared with immunocompetent individuals.2-5 The US Food and Drug Administration (FDA) and the US Centers for Disease Control and Prevention (CDC) have progressively amended COVID-19 vaccine authorizations and recommendations to include additional doses of COVID-19 vaccine for immunocompromised individuals.6,7 Following the 2-dose mRNA recommendation in December 2020, the CDC Advisory Committee on Immunization Practices recommended in August 2021 that individuals with immunocompromising conditions who had received any mRNA vaccine should receive a third dose as part of their primary series.6 In September 2021, an mRNA monovalent booster dose administered 6 months or more after completion of a primary series of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) was recommended for certain high-risk individuals, including immunocompromised individuals. For immunocompromised individuals, this booster dose corresponded to a fourth dose to follow the recommended 3-dose primary series in this population. In October 2021, the booster recommendation was expanded to recipients of any mRNA vaccine and the interval between completion of a primary series and receipt of a first booster dose was shortened to at least 5 months after completion of a primary series. In February 2022, the recommended interval between a 3-dose primary series and receipt of a first booster (ie, fourth) dose was again shortened for immunocompromised individuals, this time to at least 3 months after completion of a primary series. In March 2022, the CDC announced that immunocompromised individuals could receive a second mRNA monovalent booster of COVID-19 vaccine (ie, a fifth dose) at least 4 months after receiving their first booster (ie, their fourth dose). In May 2022, this recommendation was revised to specify that immunocompromised individuals should receive a second booster (ie, fifth dose).

This publication has 25 references indexed in Scilit: